Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay)
APLN13
(Note: Up to 8-plex in one testing reaction)
- Product No.LMB887Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample TypeSerum, plasma and other biological fluids.
- Test MethodCompetitive Inhibition
- Assay Length1.5h
- Detection Range5.86-6000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 1.953 pg/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 450
US$ 468
US$ 494
US$ 528
US$ 563
US$ 615
US$ 693
Result
For more details, please contact local distributors! US$ 866 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 80-89 | 86 |
EDTA plasma(n=5) | 84-91 | 88 |
heparin plasma(n=5) | 94-101 | 98 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 81-90% | 78-95% | 79-97% | 91-101% |
EDTA plasma(n=5) | 86-102% | 97-105% | 81-99% | 98-105% |
heparin plasma(n=5) | 80-91% | 89-101% | 80-102% | 89-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:AP13) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Investigative Ophthalmology and Visual Science | Apelin in Plasma and Vitreous and in Fibrovascular Retinal Membranes of Patients with Proliferative Diabetic Retinopathy IOVS: 4237 |
Asian Pacific Journal of Cancer Prevention | Is short-term exercise a therapeutic tool for improvement of cardioprotection against DOX-induced cardiotoxicity? An experimental controlled protocol in rats. Apjcpcontrol: Source |
Clin Exp Hypertens | Individual and concomitant effects of cardioprotective programs on cardiac apelinergic system and oxidative state in L-NAME-induced hypertension. PubMed: 22578103 |
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research | Effect of Ramadan fasting on serum concentration of apelin-13 and new obesity indices in healthy adult men NCBI: PMC3943714 |
ZJRMS | Improvement of Kidney Apelin and Apelin Receptor in Nitro-L-Arginine-Methyl Ester Induced Rats Zjrms:Source |
Iranian Journal of Kidney Diseases | The Role of Apelin 13 in Progression of Chronic Kidney Disease. PubMed: 26338160 |
Journal of Clinical & Experimental Nephrology | Role of Circulating Serum Apelin-13 Levels in Glomerulonephritis: A Pilot Study aid:8469 |
international journal of cardiology | Biochemical and genetic role of apelin in essential hypertension and acute coronarysyndrome. pubmed:27543713 |
Clinical and Experimental Hypertension | Serum concentrations of apelin-17 isoform vary in accordance to blood pressure categories in individuals with obesity class 3 Pubmed:29652188 |
Progress in Nutrition | Effect of fermented food consumption on biochemical parameters and adipokines levels Doi: 0.23751/pn.v20i4.7374 |
ACTA CARDIOLOGICA SINICA | Impact of apelin-13 on the development of coronary artery ectasia Pubmed: 32425436 |
Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
CEB887Ra | ELISA Kit for Apelin 13 (AP13) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB887Ra | Multiplex Assay Kit for Apelin 13 (AP13) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |